Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0011961 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Vera Lúcia Teixeira de Freitas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Chagas Disease, Nitroimidazoles, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeicoamento de Pessoal de Nível superior, CAPES, National Council for Scientific and Technological Development.
Abstract (Originalsprache)
Background
Trypanosoma cruzi and HIV coinfection can evolve with depression of cellular immunity and increased parasitemia. We applied quantitative PCR (qPCR) as a marker for preemptive antiparasitic treatment to avoid fatal Chagas disease reactivation and analyzed the outcome of treated cases. Methodology This mixed cross-sectional and longitudinal study included 171 Chagas disease patients, 60 coinfected with HIV. Of these 60 patients, ten showed Chagas disease reactivation, confirmed by parasites identified in the blood, cerebrospinal fluid, or tissues, 12 exhibited high parasitemia without reactivation, and 38 had low parasitemia and no reactivation.
Results
We showed, for the first time, the success of the timely introduction of benznidazole in the non-reactivated group with high levels of parasitemia detected by qPCR and the absence of parasites in reactivated cases with at least 58 days of benznidazole. All HIV+ patients with or without reactivation had a 4.0–5.1 higher chance of having parasitemia than HIV seronegative cases. A positive correlation was found between parasites and viral loads. Remarkably, treated T . cruzi/ HIV-coinfected patients had 77.3% conversion from positive to negative parasitemia compared to 19.1% of untreated patients. Additionally, untreated patients showed ~13.6 times higher Odds Ratio of having positive parasitemia in the follow-up period compared with treated patients. Treated and untreated patients showed no differences regarding the evolution of Chagas disease. The main factors associated with all-cause mortality were higher parasitemia, lower CD4 counts/μL, higher viral load, and absence of antiretroviral therapy.
Conclusion
We recommend qPCR prospective monitoring of T . cruzi parasitemia in HIV+ coinfected patients and point out the value of pre-emptive therapy for those with high parasitemia. In parallel, early antiretroviral therapy introduction is advisable, aiming at viral load control, immune response restoration, and increasing survival. We also suggest an early antiparasitic treatment for all coinfected patients, followed by effectiveness analysis alongside antiretroviral therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, São Paulo, Brazil.
- Laboratorio de Investigacao Medica em Imunologia (LIM 48), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
- Divisao de Molestias Infecciosas e Parasitarias, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
- International Health Unit Vall d'Hebron-Drassanes, Infectious Diseases Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Centre for Tropical Medicine, School of Medicine, University of Brasilia, Brasília, Distrito Federal, Brazil.
ORCID-Profile: Maria Aparecida Shikanai-Yasuda
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeicoamento de Pessoal de Nível superior, CAPES
- National Council for Scientific and Technological Development
- Research Productivity Grant
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Freitas, V. L. T., Novaes, C. T. G., Sartori, A. M. C., Carvalho, N. B., Silva, S. C. V. D., Nakanishi, É. S., Salvador, F., Castro, C. N., Bezerra, R. C., Westphalen, E. V. N., Oliveira, C. M. R., Busser, F. D., Ho, Y. L., Buccheri, R., Bonilla, C., & Shikanai-Yasuda, M. A. (2024). Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011961
Vancouver
Freitas VLT, Novaes CTG, Sartori AMC, Carvalho NB, Silva SCVD, Nakanishi ÉS, et al. Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0011961
BibTeX
@article{Freitas2024,
author = {Freitas, Vera Lúcia Teixeira de and Novaes, Christina Terra Gallafrio and Sartori, Ana Marli Christovam and Carvalho, Noemia Barbosa and Silva, Sheila Cristina Vicente da and Nakanishi, Érika Shimoda and Salvador, Fernando and Castro, Cleudson Nery de and Bezerra, Rita Cristina and Westphalen, Elizabeth Visone Nunes and Oliveira, Caroline Medeji Ramos de and Busser, Felipe Delatorre and Ho, Yeh-Li and Buccheri, Renata and Bonilla, Carolina and Shikanai-Yasuda, Maria Aparecida},
title = {Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0011961}
}
EUVIMED